- Azitra, Inc. (AZTR, Financial) is set to present its ATR04-484 program update at the 2025 ASCO Annual Meeting in Chicago.
- ATR04-484, designed to treat EGFR inhibitor-associated rash, has received Fast Track designation from the FDA.
- The Phase 1/2 clinical trial for ATR04-484 will begin dosing patients in the first half of 2025.
Azitra, Inc. (AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has announced the acceptance of an abstract detailing the Phase 1/2 clinical trial of its ATR04-484 program for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The event will be held from May 30 to June 3, 2025, in Chicago, Illinois.
ATR04-484 is a live biotherapeutic candidate using an engineered strain of Staphylococcus epidermidis and is being developed to treat skin rashes associated with Epidermal Growth Factor Receptor (EGFR) inhibitor treatments. These rashes occur due to suppressed skin immunity and inflammation, often presenting elevated levels of IL-36 and S. aureus. EGFR inhibitors are widely used in the treatment of non-small cell lung cancer and colorectal cancer.
The U.S. Food and Drug Administration (FDA) has granted ATR04-484 Fast Track designation, significantly facilitating the development and acceleration of potential new therapies that address unmet medical needs. Azitra plans to begin dosing patients in the Phase 1/2 clinical trial during the first half of 2025.
The abstracts for the ASCO Annual Meeting will be available on May 22, 2025, providing further insights into the ongoing developments of Azitra's (AZTR, Financial) ATR04-484 program. For more information about Azitra and its efforts in innovative dermatological therapies, visit their official website.
